U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGeneBusiness Wire • 04/29/25
Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?Investors Business Daily • 04/24/25
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival BenefitBenzinga • 04/03/25
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development ProgramBusiness Wire • 04/03/25
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung CancerBusiness Wire • 03/31/25
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal CancerBenzinga • 03/04/25
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with ChemotherapyBusiness Wire • 03/04/25
BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/27/25
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesBusiness Wire • 02/27/25
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27Business Wire • 02/13/25
BostonGene Collaborates with BeiGene to Advance Biomarker Discovery in Mantle Cell LymphomaBusiness Wire • 02/11/25
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with ChemotherapyBusiness Wire • 12/27/24
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/23/24
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline AssetsBusiness Wire • 12/10/24